12.06.2007 09:54:00

Johnson & Johnson Selects ArisGlobal as its Global Pharmacovigilance and Safety Partner

ArisGlobal, the leading provider of pharmacovigilance and safety systems to the life science industry, today announced its strategic partnership with Johnson & Johnson (NYSE:JNJ). Johnson & Johnson will deploy the ArisGlobal Total Safety suite of products on a global basis to replace its in-house systems. Johnson & Johnson’s goal was to select a partner who could supply a single, harmonized platform to provide global, state of the art safety case management, signal detection and surveillance capabilities. In addition, Johnson & Johnson needed a partner with a shared vision and strategy to evolve and develop systems to meet the current and future demands of a global organization such as Johnson & Johnson. Johnson & Johnson selected ArisGlobal as its partner because ArisGlobal provides the most comprehensive safety solutions on the market today, but more importantly, shares Johnson & Johnson’s vision and strategy on the future of drug safety. "We chose ArisGlobal because they understand our business environment and demonstrated excellent commitment during our business and technology requirements sessions. The services and functionality provided with ARISg combined with our development partnership with ArisGlobal to enhance ARISg will support our requirements,” said William Truhe, Vice President of Informatics, Benefit Risk Management at Johnson & Johnson Pharmaceutical Research & Development, L.L.C. "With ArisGlobal’s ARISg robust feature set, flexible data model ,intuitive user interface and ability to integrate with our key systems, Johnson & Johnson will incorporate this solution into our existing enterprise-wide processes, knowing that they have the ability to perform enhancements at an efficient pace.”. "The fact that Johnson & Johnson has entrusted ArisGlobal to support their most critical business needs is extremely satisfying. It is widely known that Johnson & Johnson has been at the forefront of drug safety initiatives and our partnership with them will allow us to develop a solid pharmacovigilance and risk management platform to satisfy the demands of government, the regulators and the consumer," said Simon Sparkes, Vice President, Global Sales and Marketing at ArisGlobal. About ArisGlobal, L.L.C. ArisGlobal, L.L.C. is a leading provider of Pharmacovigilance and Safety, Registration Information Management, Clinical Trials Management and Medical Communications software solutions to the Life Sciences industry. ArisGlobal’s software solutions are being used by over 130 life science companies around the world. ArisGlobal software helps companies meet international regulatory requirements, manage risk, improve operational efficiencies and easily share mission-critical information on a global basis. About Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Johnson & Johnson Pharmaceutical Research & Development, L.L.C., is part of Johnson & Johnson, the world's most broadly based producer of health care products. Johnson & Johnson Pharmaceutical Research & Development, L.L.C., is headquartered in Raritan, New Jersey (USA), and has facilities throughout Europe and the United States. Johnson & Johnson Pharmaceutical Research & Development, L.L.C., is leveraging drug discovery and drug development in a variety of therapeutic areas to address unmet medical needs worldwide.

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Analysen zu Johnson & Johnsonmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Johnson & Johnson 147,36 0,07% Johnson & Johnson

Indizes in diesem Artikel

Dow Jones 44 722,06 -0,31%
S&P 500 5 998,74 -0,38%
S&P 100 2 883,15 -0,41%
NYSE US 100 17 376,20 -0,02%